Thiamine Mega-Dose
Protocol
High-dose Vitamin B1 as used in practitioner protocols, with the small human studies in Alzheimer's and Parkinson's — all 4 forms, dosing tiers, paradoxical reaction warning, and required cofactors.
Build your own printable peptide tracker
A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.
Evidence at a glanceGraded by study type · every grade linked to a verified PubMed study
What we don't have: large or confirmatory trials. The only Grade-A trial is a 70-person randomized placebo-controlled Phase IIa, which its own authors describe as collecting preliminary data. The 1993 Meador study grades B: PubMed indexes it as a randomized controlled trial, but its abstract describes neither randomization nor a placebo arm, its authors present the results as preliminary, and the Gibson 2022 review describes the 1990s high-dose thiamine trials as underpowered with a small number of patients. The Parkinson's data is an open-label pilot with no control group (B). Other grades follow each study's design as stated in its title or abstract — we state the strength plainly instead of implying more.
Why Mega-Dose B1?
Standard thiamine RDA (1.1–1.2mg/day) prevents classic deficiency. Proponents of mega-dosing argue that pharmacological doses act through a different mechanism, outlined below as a hypothesis.
In this hypothesis, chronic toxicity, oxidative stress, and inflammation inactivate thiamine-dependent enzymes at the cellular level — producing a state called "functional thiamine deficiency" even when blood levels appear normal. Proponents argue that normal dietary intake cannot overcome this enzymatic blockade and that pharmacological doses are needed to restore the affected metabolic pathways; none of the human studies cited on this page tested this. This theory, developed by Dr. Derrick Lonsdale and further popularized by Elliot Overton (EO Nutrition), is offered as the reason high-dose B1 is reported to help across seemingly unrelated conditions — it remains a hypothesis, not an established mechanism.
Mitochondrial Energy
Thiamine's active form (ThDP) is a coenzyme for the pyruvate dehydrogenase and oxoglutarate (α-ketoglutarate) dehydrogenase complexes, which catalyze essential steps in glucose oxidation (Sambon 2021 review). Practitioners link reduced activity of these enzymes to fatigue and brain fog; the cited studies did not test this.
Brain & Nerve Function
Thiamine deficiency causes lesions in nerves and brain, and the thiamine-dependent enzyme complexes are needed to make neurotransmitters such as acetylcholine (Sambon 2021 review). The Meador 1993 authors note thiamine's role in acetylcholine metabolism and release; whether mega-dosing restores these pathways in people has not been established.
AGE Inhibition
In a 12-month Phase IIa trial in MCI or mild Alzheimer's, benfotiamine significantly reduced increases in blood AGE compared with placebo, an exploratory outcome (Gibson 2020). The proposed mechanism, and any relevance to other conditions, was not tested in the studies cited on this page.
Autonomic Regulation
Practitioners consider the autonomic nervous system highly thiamine-dependent and use mega-dosing for dysautonomia, POTS, and vagal tone dysregulation. None of the studies cited on this page examined these conditions.
Gene Expression
Practitioners propose that high-dose thiamine influences gene expression related to energy metabolism, inflammatory cytokines, and oxidative stress; the studies cited on this page did not measure this.
Safety
Thiamine HCl is water-soluble. TTFD is a lipophilic disulfide derivative; benfotiamine is an S-acyl (thioester) derivative that is not itself lipophilic, but is converted in the small intestine to a lipophilic metabolite (Sambon 2021 review). In a 12-month placebo-controlled trial, benfotiamine treatment was reported safe (Gibson 2020). The cited abstracts do not report adverse-event data for multi-gram thiamine HCl dosing.
4 Thiamine Forms + Research-Stage DBT
Practitioners choose a form by target condition. The cited human trials tested only thiamine and benfotiamine, and no trial has compared forms head-to-head.
| Form | Solubility | Bioavailability | BBB Crossing (practitioner-reported) | Best For | Typical Dose (practitioner protocols) |
|---|---|---|---|---|---|
| Thiamine HCl | Water-soluble | Baseline (1×) | Limited | Baseline form; given orally and intramuscularly in the cited thiamine studies | 100–500mg/day |
|
Benfotiamine Higher than HCl |
S-acyl thioester — not itself lipophilic; converted in the gut to a lipophilic metabolite | Higher than HCl | Moderate | Diabetic neuropathy (an early use, per Sambon 2021), smaller rise in blood AGE (exploratory) and Alzheimer's (investigational; Gibson 2020) | 150–600mg/day |
|
TTFD CNS focus |
Lipophilic (disulfide) | Not quantified in cited studies | High (practitioner-reported) | Practitioner use: brain/CNS, autonomic symptoms, fatigue (not tested in the cited human trials) | 25–100mg/day |
|
Sulbutiamine Nootropic |
Lipophilic (synthetic disulfide) | Not measured in cited studies | Not measured in cited studies | Sold as a nootropic — not tested in any study cited on this page | Not established in cited studies |
| Dibenzoylthiamine (DBT) | Lipophilic (thioester) | Higher than HCl (not quantified in cited studies) | Not measured in cited studies | Research stage only — more anti-inflammatory than benfotiamine in in vitro studies (Sambon 2021) | TBD |
Some practitioner protocols combine TTFD (favored for CNS use) with benfotiamine (favored for peripheral nerves and AGE inhibition), starting benfotiamine alone to assess tolerance, then introducing TTFD at a low dose (25mg) before titrating up. The intended rationale is complementary tissue coverage; no cited study tested the combination.
Which Thiamine Form Should You Buy?
Practitioner uses and the cited evidence, summarized from the comparison above — then pick it up below.
| Form | Best For | Key Trait | Buy |
|---|---|---|---|
| Benfotiamine | Peripheral nerves (practitioner use), smaller rise in blood AGE (exploratory; Gibson 2020) and Alzheimer's (investigational; Phase IIa primary endpoint not significant) | S-acyl derivative; higher bioavailability than HCl (Sambon 2021 review) | Shop → |
| TTFD (Allithiamine) | Practitioner use: brain/CNS, autonomic symptoms, fatigue (not tested in the cited human trials) | Favored for CNS use in practitioner protocols — reportedly more prone to the paradoxical reaction | Shop → |
| Sulbutiamine | Sold as a nootropic (not tested in the studies cited here) | Synthetic lipophilic B1 derivative | Shop → |
| Thiamine HCl | Cheap baseline / stacking for higher total thiamine load | Water-soluble base form; lowest cost | Shop → |
Bioavailability & CNS Penetration
A qualitative comparison; bar lengths are illustrative, not data. The plasma ordering of HCl, benfotiamine and TTFD follows the Sambon 2021 review; everything else, including all blood-brain-barrier tiers, is practitioner-reported and was not measured in humans in the studies cited on this page.
Start Low, Go Slow
The Overton/Lonsdale framework for escalating thiamine dosing — always with cofactors in place first. Practitioners report wide individual variation and treat slow titration as essential.
Phase 1: Foundation (Weeks 1–2)
Establish cofactor base before starting thiamine. Practitioners use this phase to lower the risk of paradoxical reactions and support enzymatic conversion; the cited studies did not test it.
Phase 2: Low Dose Start (Weeks 3–4)
Introduce thiamine at lowest effective dose. Monitor for paradoxical reaction (fatigue, anxiety, tachycardia, insomnia). If symptoms worsen, hold and ensure cofactors are adequate.
Phase 3: Therapeutic Titration (Weeks 5–12)
Gradually increase dose every 1–2 weeks while monitoring symptoms. May add Thiamine HCl for higher total thiamine load.
Phase 4: Maintenance / High Protocol
Practitioner protocols for serious neurological conditions (Parkinson's, Alzheimer's), typically supervised. The cited Parkinson's study (Costantini 2015) used 100 mg intramuscular thiamine twice a week; the cited oral Alzheimer's study (Meador 1993) used 3–8 g/day. Sustain cofactors throughout.
The Paradoxical Reaction
Practitioners flag this as the key thing to understand before mega-dosing, and as a reason some people stop early.
Practitioners report that some individuals experience a temporary worsening of symptoms when starting or increasing thiamine. This can manifest as increased fatigue, brain fog, anxiety, heart palpitations, insomnia, or general malaise. It is commonly attributed to a metabolic adjustment as cells ramp up ATP production, but this mechanism has not been established in clinical studies — new palpitations or other significant symptoms are a reason to stop and talk to a clinician. Practitioner reports describe the reaction as more common with TTFD than benfotiamine (not measured in the cited studies), which is why some practitioner protocols start low on benfotiamine (Shop →) before adding TTFD.
Why It Happens
The proposed explanation (not established in clinical studies): restoring oxidative energy metabolism suddenly increases metabolic demand for cofactors (especially magnesium). A temporary "nutritional debt" is called in. Proponents also suggest that rapid restoration of autonomic nerve function may trigger transient dysautonomia symptoms.
How Practitioners Manage It
If reaction occurs: Hold dose for 1 week. Increase magnesium to 300–400mg/day. Ensure complete B-complex coverage. Resume at 50% of last dose. Titrate more slowly. If symptoms are severe or persist, stop and consult a clinician.
Overton's protocol specifically warns against starting at high doses. Starting low (for example, 25mg TTFD or 100mg benfotiamine) rather than at therapeutic doses is intended to reduce paradoxical reaction severity — a practitioner rationale that none of the studies cited on this page tested.
What B1 Needs to Work
Practitioner protocols treat these cofactors as prerequisites rather than optional add-ons. The clinical studies cited on this page did not test cofactor co-administration; the doses shown are practitioner-protocol ranges, not tested targets.
What the Research Shows
The four sources graded in Evidence at a glance (three human trials and one review), plus one ungraded background review on thiamine precursors (Sambon 2021).
Morning / Evening Split
Sample practitioner-style maintenance schedule (Phase 3+); not tested in the cited studies. Adjust doses based on individual response and form selection.
Rough retail estimates; prices vary. Benfotiamine 600mg/day: ~$25–35/mo | TTFD 50mg/day (Thiamax): ~$35–50/mo | Magnesium glycinate: ~$15/mo | B-Complex: ~$10/mo | ALA 200mg: ~$12/mo | Sum of these five items: approximately $97–122/month (optional schedule items not included).
Key Takeaways
What the Evidence Supports
- In an open-label Parkinson's pilot with no control group, intramuscular high-dose thiamine was followed by improved scores (total UPDRS ~53% lower, motor part III ~55% lower; Costantini 2015)
- In a 70-person Phase IIa RCT in amnestic MCI or mild Alzheimer's, benfotiamine's primary endpoint (ADAS-Cog rise 43% lower vs placebo) was not statistically significant (p = 0.125); the secondary CDR endpoint worsened 77% less (p = 0.034) (Gibson 2020)
- Benfotiamine treatment was reported safe over 12 months in an Alzheimer's Phase IIa RCT (Gibson 2020)
Limitations & Unknowns
- Most thiamine neuroprotection studies are small, open-label, or pilot stage — Phase III RCTs needed
- Optimal dosing for specific conditions is not yet standardized
- Paradoxical reactions are described in practitioner reports, sometimes as severe; their frequency and severity have not been measured in the cited studies
- Anecdotal reports of sulbutiamine tolerance lead some users to cycle it rather than take it daily long-term; this has not been well studied
- Dibenzoylthiamine is research-stage; the cited review reports only in vitro and mouse data
- No head-to-head comparison trials between thiamine forms for neurological endpoints
- Mechanism of paradoxical reaction not fully elucidated in clinical literature
- The "functional deficiency" explanation is a hypothesis — the Parkinson's pilot authors propose a thiamine-dependent metabolic dysfunction, but it has not been established
- TTFD's reputation for superior CNS penetration rests on practitioner sources; none of the cited human trials tested TTFD
- Start-low-go-slow titration and cofactor priming (magnesium, B-complex, potassium) are practitioner recommendations; no cited study has tested them
Recommended Products
Everything you need for a complete thiamine mega-dose protocol
Affiliate links support HighPeptides at no extra cost.
Related Research
Deep dives into each thiamine form and related cognitive-support compounds
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.
Get the Guide: $19 (normally $29) →
The Peptide Buyer’s Playbook ($19)
67-page guide: protocols, dosing, sourcing. Everything in one place.
Get the guide: $19 (normally $29) → The Peptide Buyer’s Playbook ($19) All ebooks & guides →Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.